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Abstract
Purpose To evaluate the effects of probiotic supplementation on gastrointestinal (GI) symptoms, circulatory markers of GI 
permeability, damage, and markers of immune response during a marathon race.
Methods Twenty-four recreational runners were randomly assigned to either supplement with a probiotic (PRO) capsule 
[25 billion CFU Lactobacillus acidophilus (CUL60 and CUL21), Bifidobacterium bifidum (CUL20), and Bifidobacterium 
animalis subs p. Lactis (CUL34)] or placebo (PLC) for 28 days prior to a marathon race. GI symptoms were recorded during 
the supplement period and during the race. Serum lactulose:rhamnose ratio, and plasma intestinal-fatty acid binding protein, 
sCD14, and cytokines were measured pre- and post-races.
Results Prevalence of moderate GI symptoms reported were lower during the third and fourth weeks of the supplement 
period compared to the first and second weeks in PRO (p < 0.05) but not PLC (p > 0.05). During the marathon, GI symptom 
severity during the final third was significantly lower in PRO compared to PLC (p = 0.010). The lower symptom severity 
was associated with a significant difference in reduction of average speed from the first to the last third of the race between 
PLC (− 14.2 ± 5.8%) and PRO (− 7.9 ± 7.5%) (p = 0.04), although there was no difference in finish times between groups 
(p > 0.05). Circulatory measures increased to a similar extent between PRO and PLC (p > 0.05).
Conclusion Probiotics supplementation was associated with a lower incidence and severity of GI symptoms in marathon 
runners, although the exact mechanisms are yet to be elucidated. Reducing GI symptoms during marathon running may help 
maintain running pace during the latter stages of racing.
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Introduction
Gastrointestinal (GI) symptoms are widely reported in ath-
letes participating in prolonged endurance events (Costa 
et al. 2017a). In marathon running, 27% of recreational run-
ners report moderate or more severe GI symptoms during 
a race (Pugh et al. 2018). The pathogenesis of such symp-
tomology is still poorly understood, although it is likely 
multifactorial in nature. The exercise-induced reduction in 
splanchnic blood flow is well characterised (Otte et al. 2001) 
and results in dysregulation of the intestinal barrier. This 
likely leads to endotoxemia and an immunological response, 
which has been associated with GI symptoms during ultra-
endurance events (Jeukendrup et al. 2000). Carbohydrate 
(CHO) intake during exercise is also suggested to be a poten-
tial causative and or aggravating factor, due to malabsorption 
when consumed in excess (de Oliveira and Burini 2014), 
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although tolerance levels may differ for individuals (Costa 
et al. 2017b). There may also be a predisposition to symp-
toms, as individuals with a history of recurrent exercise-
associated GI symptoms, appear to suffer greater prevalence 
and severity of symptoms during exercise (Ter Steege et al. 
2008). However, due to the range of symptom types (each 
with their own unique aetiology) coupled with differences 
in study methodologies to assess GI symptoms, studies to 
date have yet to find a single mechanism. Nonetheless, GI 
symptoms during marathon running remain detrimental to 
exercise performance in recreational and elite runners (Pugh 
et al. 2018) hence potential strategies to reduce such remains 
an attractive area of research.
One potential strategy to reduce GI symptoms during 
endurance exercise is probiotic supplementation (Roberts 
et al. 2016). While probiotics can relieve lower GI symptoms 
in irritable bowel syndrome IBS (Hungin et al. 2018), there 
is less consensus with regard to their efficacy in modulating 
exercise-associated GI symptoms. A reduction in the dura-
tion of GI symptoms was noted in a group of recreational 
runners 2 week post-marathon race following a single strain 
probiotic supplementation, although only severe symptoms 
(diarrhea, vomiting, and stomach ache) were recorded and 
no differences were found during the period of supplementa-
tion (Kekkonen et al. 2007). The severity of GI symptoms 
during training in novice triathletes was also reduced when 
supplementing with a multi-strain probiotic, with subsequent 
reductions in GI permeability following an Ironman distance 
triathlon race compared to placebo (Roberts et al. 2016). 
However, permeability was assessed 6 day post-race and in-
race GI symptoms were not assessed. Potential mechanisms 
by which symptoms could be ameliorated include modula-
tion of CHO absorption and oxidation (Rooj et al. 2010), and 
attenuation of exercise-induced GI damage or permeability 
(Anderson et al. 2010; Lamprecht et al. 2012).
There are many circulatory markers of GI dysfunction 
that have been assessed post-exercise. Indirect measures 
of GI permeability utilise dual sugar probes, such as lactu-
lose and rhamnose (Pugh et al. 2017b), while intestinal-
fatty acid binding protein (I-FABP) has often been used 
as a sensitive marker to intestinal mucosal damage (Pugh 
et al. 2017a; Van Wijck et al. 2011). However, the rela-
tionship between such markers and exercise-induced GI 
symptoms is unclear. Downstream circulatory markers of 
immune activation and inflammatory response have been 
assessed following competitive endurance exercise (Moore 
et al. 1995; Nieman et al. 2006), although to date, only 
one marker has been associated with the occurrence of 
GI symptoms. Plasma soluble cluster of differentiation 14 
(sCD14) is a co-receptor of lipopolysaccharide (LPS) and 
a marker of monocyte activation (Shive et al. 2015). Post-
race plasma concentrations of sCD14 were increased to a 
greater extent in ultramarathon runners reporting symp-
toms of nausea relative to those without (Stuempfle et al. 
2016). Therefore, sCD14 warrants further investigation 
following endurance exercise.
Given the prevalence of GI issues in endurance athletes 
and the associated effects on exercise performance and per-
ceived enjoyment, the purpose of this study was to evaluate 
the effects of probiotic supplementation on GI symptoms 
during marathon training and racing. We hypothesised that 
GI symptoms during training and a marathon race would be 
less frequent and less severe with probiotic supplementation. 
In addition, it was hypothesised that probiotic supplementa-
tion would attenuate circulatory markers of exercise-induced 
GI permeability, damage, and immunological response.
Methods
A total of 24 runners (20 male, 4 female) participated in the 
study. All participants were required to have run a marathon 
race quicker than 5 h within the previous 2 years. Partici-
pant characteristics are presented in Table 1. All participants 
were free of medications, such as NSAIDs, antidepressants, 
or diuretics, nutritional supplements and any history of GI-
related medical issues (IBS or abdominal surgery). After 
explaining the nature and risks of the experimental proce-
dures to the participants, their informed written consent was 
obtained. The study was approved by the Ethics Committee 
of Liverpool John Moores University.
Table 1  Participant 
characteristics
Values are mean ± SD. Differences between groups for all measures were not significant
PLC PRO
Mean ± SD Range Mean ± SD Range
Age (years) 36.1 ± 7.5 29–50 34.8 ± 6.9 22–43
Height (cm) 175.4 ± 11.1 152–186 179.0 ± 6.3 168–190
Body mass (kg) 73.5 ± 11.3 48–95 76.5 ± 9.4 61–92
V̇O2peak (mL kg min−1) 56.4 ± 8.6 47.2–70.0 57.6 ± 8.0 48.1–66.7
LT (km h−1) 11.9 ± 1.9 9–16.0 12.3 ± 1.9 10–15.5
Most recent marathon time (min) 220 ± 40 150–283 222 ± 46 152–315
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Baseline testing
At least 4 weeks before the marathon, and prior to the sup-
plement period, participants visited the laboratory and com-
pleted the Gastrointestinal Symptom Rating Scale (Svedlund 
et al. 1988) to assess baseline GI symptoms. Participants 
then completed an incremental running test to determine 
lactate threshold (LT) and peak oxygen uptake ( V̇O2peak) 
as previously described (Jones 2006). Briefly, participants 
ran a minimum of six stages on a motorized treadmill (HP 
Cosmos Saturn, Traunstein, Germany). Each stage was 
3 min in duration and interspersed with 30 s breaks to allow 
blood sampling. Running speed was increased by 1 km h−1 
at the end of each stage, until runners reached volitional 
exhaustion.
Supplement period
After baseline testing, in a double-blind, randomised and 
matched-pairs design, participants underwent a 28  day 
period of supplementation consuming either a commer-
cially available probiotic (PRO) or a visually identical 
placebo (PLC). Participants also consumed an additional 
supplement capsule on the morning of the race, 2 h before 
the start. Participants were matched according to their most 
recent marathon performance (PRO: 222 ± 46 min; PLC 
220 ± 40 min) and body mass (Table 1). The probiotic sup-
plement capsules contained the active strains Lactobacillus 
acidophilus CUL60, L. acidophilus CUL21, Bifidobacte-
rium bifidum CUL20, and Bifidobacterium animalis subsp. 
Lactis CUL34 (Proven Probiotics Ltd, Port Talbot, Wales). 
The minimum concentration was 25 billion colony-forming 
units (CFU) per capsule. The placebo capsules were visually 
identical and consisted of cornstarch only (Proven Probiot-
ics Ltd, Port Talbot, Wales). Participants were instructed to 
swallow the capsule daily after their first meal. The randomi-
zation code was held by a third party, unlocked for analyses 
upon sample analysis completion. During the supplementa-
tion period, participants were instructed to refrain from all 
probiotic foods (i.e., fermented yogurts). For the full 28 day 
supplement period, participants were required to complete 
a daily training and GI symptom diary. Six GI symptoms 
were included: bloating, nausea, urge to vomit (upper GI), 
flatulence, urge to defecate, and stomach cramps (lower GI). 
Symptoms were scored from 0 to 10 on a visual analogue 
scale. Symptoms scored ≥ 4 were classified as ‘moderate’ 
or worse and these data were summed during the supple-
mentary period.
Marathon race
During the 24 h before the race, participants consumed a 
standardized high CHO, low fibre diet [per kg body mass: 
8.0 g CHO (0.28 g fibre); 2.0 g protein; 1.0 g fat]. Compli-
ance to the diet was confirmed with food diaries and the 
remote food photography method (Martin et al. 2009). After 
an overnight fast, participants reported to the laboratory at 
~ 07:00 h and resting blood samples were taken. Participants 
were then provided a standardized breakfast [572 kcal; 128 g 
CHO (4.4 g fibre), 7 g protein, 3.5 g fat, and a minimum 
of 500 mL water] before a pre-race venous blood sample 
was collected. Participants performed self-selected warm-
ups before a race briefing to reiterate in-race nutrition and 
subjective measures. The race started at 12:00 pm. Runners 
ran the 42,195 m race on a synthetic 400 m outdoor track 
(105.48 laps) which was in close proximity to the laboratory. 
Weather conditions throughout the race were: temperature: 
16–17 °C; wind speed: 8–16 km h−1; precipitation: 0 mm. 
During the race, heart rate was monitored throughout (First-
beat Sports©, Jyväskylä, Finland) and subjective ratings of 
perceived exertion (RPE) (Borg 1970) were recorded every 
15 min. Each 400 m lap time was recorded using electronic 
chips and a timing mat (BibTag System, MYLAPS, USA). 
Global GI discomfort was assessed every 15 min using a 
modified Likert scale (Nieman et al. 2006). These physiolog-
ical and symptomology data were consolidated and reported 
as the mean of each third of the race distance completed, 
given that reductions in average running pace and reporting 
of ‘hitting the wall’ are seen after 25–30 km (Santos-Lozano 
et al. 2014; Buman et al. 2009), and glycogen depletion is 
theorised to occur between 32 and 40 km (Locksley 1980).
In‑race nutrition
Participants consumed one 60 mL CHO gel (SIS Isotonic 
Gel, Blackburn, UK) and 200 mL of water 10–15 min before 
the start of the race and one 60 mL CHO gel with 200 mL 
of water 40 min after the start of the race and subsequently 
every 20 min for the remainder of the race. Gels consisted of 
22 g maltodextrin and 0.01 g sodium. This provided an aver-
age of 66 g h−1 CHO in 180 mL and 600 mL h−1 of water 
during the race, a strategy that has been shown to improve 
performance in non-elite runners relative to a self-selected 
strategy (Hansen et al. 2014). To familiarize with this nutri-
tional strategy, participants were informed of the strategy 
and provided with identical gels to practice this during their 
two longest training runs during the prior 4 week supple-
mentation period. This was diarized in the GI symptom and 
training diary.
Post‑race
Blood samples were collected immediately post-race for 
later analysis. Participants were then asked to complete a 
more detailed questionnaire (adapted from Pfeiffer et al. 
2012) to assess any specific symptoms of GI discomfort, 
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including: bloating, flatulence, stitch, belching, nausea, urge 
to vomit, urge to defecate, and stomach cramps. These were 
scored on a 10-point scale (0 = no pain and 10 = worst pos-
sible pain) with a score > 4 being regarded as moderate. To 
ensure understanding, specific symptoms were explained 
and described to participants. This same scale was used in 
the daily GI symptom diary used during the supplementa-
tion period.
Blood analysis
Blood samples were collected into vacutainers containing 
EDTA, lithium heparin, and serum separation tubes. From 
whole blood samples, duplicate measures of haematocrit 
(Hawksley micro-haematocrit reader, Sussex, UK) and 
haemoglobin (Haemocue, Sussex, UK) were taken. Serum 
samples were allowed to clot for 1 h at room temperature, 
while EDTA and lithium heparin samples were imme-
diately stored on ice, following which all samples were 
centrifuged for 15 min at 1500 RCF at 4 °C. Serum and 
plasma were manually extracted and stored at − 80 °C until 
required for analysis. Samples were analysed for plasma 
glucose, intestinal-fatty acid binding protein (I-FABP), 
sCD14, interleukin-6 (IL-6), IL-8, IL-10, and serum cor-
tisol. Post-race sample concentrations were corrected for 
plasma volume changes as described by Dill and Costill 
(1974).
Intestinal permeability was assessed by analysing serum 
samples using a previously published protocol (Fleming 
et al. 1996), with the modification of using rhamnose instead 
of mannitol as the monosaccharide probe. Briefly, at base-
line, a 50 mL sugar probe solution (5 g lactulose, 2 g rham-
nose) was consumed and the ratio of the sugars was meas-
ured from serum samples 60 min after ingestion. A second 
identical probe was consumed immediately post-race and 
serum samples taken after 60 min for LR assessment. Pilot 
testing within our laboratory showed that after consuming 
the LR probe, serum lactulose and rhamnose concentrations 
had returned to baseline 7 h post ingestion and that a second 
LR probe at this time was able to detect post-exercise LR 
increase relative to a morning resting sample, which was 
also demonstrated on race day (Fig. 1b, c).
Concentrations of I-FABP from EDTA plasma were 
determined using an ELISA (Hycult Biotechnology, Uden, 
The Netherlands; detection window 47–5000 pg mL−1) 
according to the manufacturer’s instructions. The coefficient 
of variation (CV) was 8.0% for between-sample duplicates. 
Plasma sCD14 was measured with a commercial enzyme-
linked immunosorbent assay kit (R&D Systems, Inc., Min-
neapolis, Minnesota, USA) according to the manufacturer’s 
instructions, with a CV of 5.9%. Cytokine concentrations 
were measured using cytometric bead array (CBA, BD Bio-
sciences, San Diego, USA) for the cytokines IL-6, IL-8, and 
IL-10 using the manufacturer’s instructions with three bead 
populations with distinct fluorescence intensities coated with 
capture antibodies specific for IL-6, IL-8, and IL-10 proteins 
with analysis on a BD Accuri flow cytometer (Becton–Dick-
inson, Franklin Lakes, NJ, USA). Following acquisition of 
sample data using the flow cytometer, the sample results 
were generated in graphical and tabular format using the 
BD CBA Analysis Software. The combined coefficients of 
variation were 9.7%. Serum cortisol was measured using 
Fig. 1  Serum lactulose:rhamnose ratio (a), laculose (b), and rham-
nose concentrations (c) at each sampling point. *Significant dif-
ference from pre-race (p < 0.05), #significant difference to post LR 
(p < 0.05)
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an ELISA kit according to the manufacturer’s instructions 
(Elecsys Cortisol assay, Cobas-Roche, UK), with a CV of 
2.9%.
Statistical analysis
Descriptive statistics were produced for all data sets to 
check for normal distribution indicated by Shapiro–Wilk 
test (accepted if p > 0.05). A two-factor mixed measures 
ANOVA was used to examine differences in LR, I-FABP, 
sCD14, cytokines, and cortisol with condition (PRO and 
PLC) and various timepoints as the independent variables. 
Where significant main effects and interactions were present, 
pairwise comparisons were performed using the Sidak test 
method. For physiological and symptomology measures, 
individual data points were consolidated and averaged for 
each third of the race distance covered. To evaluate data on 
GI symptoms, a nonparametric statistical approach was cho-
sen, as scores on GI symptoms were mainly reported on the 
low end of the scale and not normally distributed. Symptom 
diary variables were compared with the use of Wilcoxon 
Signed Rank tests. GI symptom diary data were analysed as 
the sum of all moderate or worse symptoms (scale of 0–84; 
a maximum of 6 each day) and the total number of days in 
which any GI symptoms ≥ 4 were reported. Symptom scores 
during the race were compared with the use of Mann–Whit-
ney nonparametric U test for independent data. Spearman 
rank-order correlation was used to analyse the relationship 
between GI symptoms, with post-exercise I-FABP, inflam-
matory cytokines, and sCD14 concentrations. All normally 
distributed data are presented as mean ± standard deviation 
(SD). Data not normally distributed are reported as median 
and range. p < 0.05 was considered statistically significant. 
Statistical analysis was conducted using the Statistical Pack-
age for the Social Sciences software programme (SPSS, ver-
sion 23) and Prism statistical software (GraphPad Prism, 
version.7.0c, La Jolla, CA, USA).
Results
GI symptoms during supplementary period
Baseline assessment scores from the GSRS showed no 
differences in GI symptoms between groups for any indi-
vidual symptom, lower GI, upper GI, or total GI symp-
tom scores (data not shown). From GI symptom diaries, 
daily average scores for specific symptoms were low (< 2) 
in both PRO and PLC. However, there was a large range 
of scores for individual symptoms, with 17 participants 
reporting symptoms with moderate severity or worse dur-
ing at least 1 day. Table 2 displays the median number of 
total symptoms scored as moderate (≥ 4) for upper and 
lower GI symptoms, as well as the number of days with 
one or more moderate symptom. Data are shown for the 
first 14 days and the second 14 days. For the probiotic 
group, there were significant reductions in the number of 
moderate symptoms reported as well as the number of days 
in which moderate symptoms were reported in the sec-
ond two of supplementation compared to the first 2 weeks 
(Table 2). There were no differences in the placebo group.
Race completion and sample collection
A total of 20 runners completed the marathon race. There 
was one drop-out from PRO and three from PLC. Partici-
pants were asked to self-describe their reason for drop-out. 
In PLC, participants withdrew from the race due to muscu-
loskeletal injury (22.5 km of the race completed) and two 
due to severe GI discomfort (12.2 and 30.2 km). In the PRO 
group, withdrawal was due to reflux (13.4 km). Those run-
ners who completed at least 50% of the total were included 
for analysis for all blood analysis, and all participants were 
included for GI symptom scores during training. Blood 
samples could not be obtained at any timepoint from one 
participant who completed the race. All athletes were 100% 
compliant to the in-race water prescription. Adherence to the 
gel consumption nutritional plan was high with only one gel 
missed by three participants (2 PLA and 1 PRO).
Table 2  GI symptoms reported during days 1–14 and 15–28 days during supplementation
Data are presented as median and range
*Significant difference between days 1–14 and 15–28 (p < 0.05) (Mann–Whitney U test)
PRO PLC
Days 1–14 Days 15–28 Wilcoxon p value Days 1–14 Days 15–28 Wilcoxon p value
Total number of GI scores ≥ 4 4 (0–25) 2 (0–16) 0.007* 5 (0–41) 11 (0–39) 0.336
Total number of upper GI scores ≥ 4 0 (0–10) 0 (0–10) 0.317 3 (0–8) 3 (0–6) 0.514
Total number of lower GI scores ≥ 4 3 (0–16) 1 (0–8) 0.007* 4 (0–11) 5 (0–12) 0.317
Number of days with one or more 
symptom scored ≥ 4
3 (0–12) 1 (0–6) 0.011* 5 (0–12) 5 (0–10) 0.579
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Overview of marathon performance
Participants completed the marathon in times between 152 
and 302 min (Table 3). For all physiological measures, 
there were no significant differences between PLC and PRO 
(p > 0.05). For HR and RPE, data are shown for each third of 
the race distance. For all participants, RPE increased from 
the first to the final third (p < 0.001) of the race. Post-race 
blood glucose concentrations were increased in both groups 
relative to pre-race samples (p < 0.001).
Mean running speed during each lap for PLC and PRO is 
shown in Fig. 2a. Average running speeds were calculated 
for both groups during each third of the race and relative 
comparisons were made between each third (Fig. 2b). Dur-
ing the second third of the race, relative reductions in speed 
were 3.6 ± 3.5% for PRO and 6.9 ± 6.9% for PLC, although 
this was not significant (p = 0.165). During the final third, 
the reduction in average relative speed was greater in PLC 
(14.2 ± 5.8%) compared to PRO (7.9 ± 7.5%) (p = 0.03). 
This difference also remained significant between PLC 
(14.1 ± 6.1) and PRO (8.0 ± 6.7%) when only matched pairs 
were considered (n = 8 per group) (p = 0.04).
Global GI symptoms during the race
During the race, global GI scores were averaged across each 
third (Fig. 2c). There were significant effects of both time 
(p < 0.001) and condition (p = 0.03). For time, there no sig-
nificant differences between thirds for PRO. For PLC, there 
was a significant difference between GI symptom scores 
between the first (1.6 ± 1.8) and final third (6.1 ± 2.7) of 
the race (p < 0.001). While differences between conditions, 
groups were not significant for the first (p = 0.722) or second 
(p = 0.205) third of the race, GI symptoms were significantly 
lower in PRO compared with PLC during the final third of 
the race (p = 0.010) (Fig. 2c). When only matched pairs 
were considered (n = 8 per group), GI symptoms were still 
significantly higher in the final third (5.6 ± 2.9) of the race 
compared to the first (1.5 ± 2.0) for PLC (p = 0.001). The 
difference in GI symptoms scores between groups during 
the final third of the race only trended towards significance 
(p = 0.08) between PLC (5.6 ± 2.9) and PRO (3.25 ± 2.1). 
For both groups combined (n = 20), there was a significant 
correlation between average global GI score in the final 
third, and a reduction in average pace during this final third 
relative to the first third (r = 0.562, p = 0.010) (Fig. 2d).
Circulatory markers of immune activation and GI 
dysregulation
Differences in sCD14 between PRO and PLC were not 
significant either pre- or post-race (Fig.  3a). For both 
groups, sCD14 was significantly increased post-race 
(PLC = 8.7 ± 5.1 µg mL−1, PRO = 9.6 ± 5.7 µg mL−1) com-
pared to pre-race (PLC 3.3 ± 1.7 µg mL−1, p = 0.006; PRO 
3.7 ± 1.6 µg mL−1, p = 0.022). Changes in pre-to-post-race 
sCD14 concentrations were significantly correlated with a 
global GI symptoms reported during the final third of the 
race (r = 0.546, p = 0.016).
Differences in LR (Fig. 1a) and I-FABP (Fig. 3b) were 
not significant at any timepoints between PRO and PLC. 
There was a significant effect of time for LR with a sig-
nificant difference between pre- (PRO = 0.057 ± 0.022; 
P L C  =  0 . 0 6 1  ±  0 . 0 4 2 )  a n d  p o s t - r a c e  va l u e s 
(PRO = 0.099 ± 0.062; PLC = 0.081 ± 0.036) (p = 0.040). 
Differences in LR pre-to-post-race were due to significant 
increases in serum lactulose concentration 1 h post-race 
compared to post LR (Fig. 1b), while there was no signifi-
cant difference in serum rhamnose concentrations at these 
timepoints (Fig. 1c). For both groups, I-FABP was signifi-
cantly increased post-race (PRO = 1814 ± 1708 pg mL−1; 
PLC = 1392 ± 867 pg mL−1) compared to pre-race (PRO 
455 ± 190 pg mL−1; PLC 460 ± 221 pg mL−1) (p = 0.0004). 
The difference was not significant at 1  h post-race 
(p = 0.925). Post-race values for LR (r = − 0.250, p = 0.289), 
changes in pre-to-post-race LR (r = − 0.275, p = 0.24), and 
Table 3  Physiological responses to the marathon
Data are mean ± SD
a Significantly different to 1/3 race distance (p < 0.001)
b Significantly different to pre-race (p < 0.001)
Timepoint PLC (n = 9) PRO (n = 11)
Finish time (min) 247 ± 47 234 ± 38
Running speed (%LT) 91.3 ± 8.7 90.2 ± 9.1
Heart rate (bpm)
 1/3 of race 162 ± 9 156 ± 13
 2/3 161 ± 15 160 ± 9
 3/3 155 ± 19 161 ± 8
RPE
 1/3 of race 12.6 ± 0.7 12.5 ± 1.0
 2/3 14.5 ± 0.9 14.8 ± 1.8
 3/3 16.5 ± 1.7a 16.3 ± 2.5a
Blood glucose (mmol L−1)
 Pre 5.3 ± 0.6 5.2 ± 1.1
 Post 7.5 ± 1.1b 8.4 ± 1.6b
Haemoglobin (g dL−1)
 Pre 14.2 ± 0.9 13.8 ± 1.6
 Post 13.8 ± 1.9 13.9 ± 12
Haematocrit (%)
 Pre 42.5 ± 3.2 41.5 ± 3.7
 Post 42.9 ± 4.2 42.6 ± 3.1
PV change (%) 2.1 ± 8.4 − 1.4 ± 6.8
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Fig. 2  a Running speed during each lap of the race. b Average run-
ning speed during each third of the race, relative to first third. *Sig-
nificant difference between PLC and PRO (p < 0.05). c Global GI 
symptom scores during each third of the race. *Significant increase 
compared to PRO. d Correlation between relative decline in speed 
and average global GI symptom scores during the final third of the 
race
Fig. 3  a Plasma sCD14 concentrations pre- and post-race for PRO 
(n = 11) and PLC (n = 10) groups. *Significant difference from 
pre-race (p < 0.05). b Plasma intestinal-fatty acid binding protein 
(I-FABP) pre-, post-, and 1 h post-race for PRO and PLC. *Signifi-
cant difference from pre-race (p < 0.05)
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changes in pre-to-post-race concentrations of I-FABP 
(r = − 0.481, p = 0.075) did not significantly correlate with 
global GI symptom scores.
The concentrations of IL-6, IL-8, IL-10, and cortisol are 
presented in Table 4. There were no significant differences 
for either pre- or post-race concentrations between PLC and 
PRO (p > 0.05). For both groups, all measures increased 
from pre- to post-races (p < 0.001). Post-race values did not 
correlate with global GI symptom scores (p > 0.05).
GI symptoms assessed post‑race
Mean scores for specific symptoms immediately post-race 
and 24 h post were all low for both PRO and PLC (≤ 2) 
with no significant differences between conditions for all 
symptoms. From these, total, upper, and lower GI symp-
tom scores were calculated, with no significant differences 
between PRO and PLC (Table 5). All participants reported 
at least one symptom during the race and 24 h post-race 
(score ≥ 2), while 50% reported at least one moderate symp-
tom (score ≥ 4). Correlations between measures of either 
any of the individual specific GI measures, or pooled totals 
(total score, lower GI score, and upper GI score) assessed 
post-race and global GI symptoms were all not significant 
(p > 0.05).
Discussion
The aim of the present study was to evaluate the effects of 
probiotic supplementation on gastrointestinal (GI) symp-
toms, circulatory markers of GI permeability and damage, 
cytokines and cortisol during a marathon race. Utilising an 
officially sanctioned track marathon race in a wide range of 
experienced marathon runners, we report that all runners 
experienced GI symptoms, with two athletes abandoning the 
race due to severe GI discomfort. Of note, there was an asso-
ciation between the subjective scores of in-race GI symp-
toms and reductions in running speed, especially towards the 
later stages of the race. We report for the first time that run-
ners supplementing with probiotics reported fewer and less 
severe GI symptoms, both in training and during a marathon 
race when using standardized, recommended CHO loading 
and in-race CHO and hydration strategies. Those runners 
supplementing with probiotics also demonstrated less of a 
performance decrement (as evidenced by maintaining run-
ning speed) towards the end of the race. Taken together, our 
data suggest that supplementation with probiotics could have 
performance benefits during competitive endurance exercise 
through alleviation of GI symptoms.
In relation with the 4 week supplementation period, our 
data demonstrate that participants reported fewer moder-
ate GI symptoms during training (as reported in a daily GI 
symptom diary), an effect that was observed after 2 weeks of 
probiotic supplementation. In subsequently assessing global 
GI symptoms using a visual analogue scale during the mara-
thon race itself, we were also able to report, in real time, the 
development of GI symptoms throughout the race. As each 
400 m lap time was recorded, we were able to accurately 
assess running speed throughout the race and observed a 
significant association between GI symptom severity and 
the reduction in running speed during the final third of the 
race. From the measurements of real-time GI symptoms and 
reductions in speed, our data, therefore, suggest that pro-
biotic supplementation could help marathon runners better 
maintain their running speed, possibly due to the attenuation 
of GI symptoms. Previously, a ‘gut-training’ protocol that 
was able to reduce GI symptoms during exercise resulted in 
an increase in endurance performance, supporting a causal 
relationship between GI symptom severity and decrements 
Table 4  Pre- and post-
exercise cytokine and cortisol 
concentrations for placebo 
and probiotic groups. Data are 
mean ± SD
a Significant difference from pre-race (p < 0.001)
PLC PRO
Pre-race Post-race Pre-race Post-race
IL-6 (pg mL−1) 0.82 ± 0.74 13.58 ± 12.9a 1.01 ± 0.66 10.96 ± 7.86a
IL-8 (pg mL−1) 2.13 ± 2.03 12.11 ± 6.33a 2.24 ± 0.92 13.45 ± 11.18a
IL-10 (pg mL−1) 0.73 ± 0.64 5.78 ± 3.26a 0.91 ± 0.55 5.27 ± 3.91a
Cortisol (nmol L−1) 614 ± 119 1083 ± 196a 653 ± 155 1148 ± 242a
Table 5  GI symptoms measured immediately and 24 h post-race
Data are presented as median and range
PLC PRO
Immediately post-race
 Total GI symptom score 15 (3–51) 13 (0–37)
 Upper GI symptom score 5 (0–30) 6 (0–16)
 Lower GI symptom score 7 (0–21) 10 (0–31)
24 h post-race
 Total GI symptom score 12 (0–43) 16 (0–36)
 Upper GI symptom score 4 (0–46) 6 (0–18)
 Lower GI symptom score 5 (0–25) 7 (0–28)
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in performance (Miall et al. 2018). However, it is also known 
that reductions in running speed during the final stages of a 
marathon can elicit negative emotions (Buman et al. 2008), 
and therefore, we cannot exclude the possibility that GI 
symptom scores may have been higher or exaggerated in 
those runners whom were unable to maintain their race pace. 
Regardless of the exact reason for the maintenance of race 
pace, data presented here have shown the potential of pro-
biotic supplementation to improve endurance performance, 
where GI symptoms are likely to be a deleterious factor.
We (Pugh et al. 2018) and others (Pfeiffer et al. 2012; Ter 
Steege et al. 2008) have previously reported that 4–27% of 
runners report ‘moderate’ or ‘serious’ GI symptoms during 
a marathon race (Pfeiffer et al. 2012; Ter Steege et al. 2008; 
Pugh et al. 2018). In the current study, 50% of participants 
reported experiencing one or more moderate symptoms dur-
ing the race. Interestingly, when specific GI symptoms were 
assessed immediately post-race, there was no association 
with these and global in-race symptoms. This discrepancy 
may present a discourse between measures recorded in real 
time and measures requiring recall. The higher incidence 
reported here may also be due to the higher CHO consump-
tion (66 g h−1) than ab libitum intakes reported previously 
(35 ± 26 g h−1) (Pfeiffer et al. 2012). This may also explain 
why studies conducted to date have not shown an association 
with CHO intake during marathon running and GI symp-
toms (Hansen et al. 2014; Pfeiffer et al. 2012; Pugh et al. 
2018).
As well as an association with GI symptoms and reduc-
tions in running speed, there were significant correlations 
between GI symptoms and post-race sCD14 concentrations, 
although there were no differences between supplement 
groups. sCD14 has previously been described as a marker 
for increased exposure to lipopolysaccharides (Wright 
et al. 1990), the translocation of which triggers an immune 
response thought to be an aetiological factor for exercise-
induced GI symptoms (Costa et al. 2017a). During a 161 km 
ultramarathon, plasma sCD14 concentrations were signifi-
cantly higher post-race in those participants reporting symp-
toms of nausea (Stuempfle et al. 2016). It should be noted 
that while sCD14 is stimulated by lipopolysaccharide, it can 
also be stimulated by a number of toll-like receptor ligands 
and inflammatory cytokines and so may better be considered 
a marker of monocyte activation (Shive et al. 2015). How-
ever, the lack of any significant correlations between plasma 
cytokine and sCD14 concentrations in the present study is 
unsurprising given that strenuous exercise is a strong stimu-
lus for cytokine production, independent of GI damage and 
GI translocation (Pedersen and Hoffman-Goetz 2000). While 
we acknowledge that we did not observe an effect of probi-
otic supplementation on post-race sCD14 concentrations, 
our data do suggest that sCD14 may be a novel marker for 
GI-induced immune activation following endurance exercise 
and provides scope for future research.
There was no association between GI symptoms and LR 
or I-FABP (used as a marker of GI permeability and dam-
age, respectively), although both were increased post-race. 
Previously, GI permeability has been shown to be increased 
following a half and full marathon, but without correla-
tion to any GI symptoms (Smetanka et al. 1999; Oktedalen 
et al. 1992). Indeed, an inverse correlation between exer-
cise-induced GI permeability and symptoms has also been 
reported (Costa et al. 2017b), where those with the highest 
GI permeability reported the lowest symptoms, a finding that 
has also been found with I-FABP (Costa et al. 2017b). While 
these markers of GI permeability and damage may have 
clinical relevance, the lack of relationship with GI symp-
toms seen here and in the previous studies reinforces both 
the complexities and difficulties in assessing the deleterious 
effects of exercise on the GI tract, its ability to retain func-
tionality during endurance exercise, and the mechanisms of 
individual GI symptoms. Future studies, particularly field-
based studies, must, therefore, consider an array of circu-
latory and subjective measures, although more invasive 
measures could be needed to fully understand the aetiology 
of symptoms.
Despite the novel data presented here that adds to the 
current literature, it is not without some limitations, most of 
which are due to the using a real-life, competitive marathon 
race within the study design. Indeed, while the study holds 
methodological rigor in standardising many of the variables 
that can affect the incidence of exercise-induced symptoms 
such as pre-race nutrition, we also acknowledge that the use 
of an absolute CHO and water intake may not have been 
the optimum in-race nutrition strategy for each individual. 
It is known that many components of digestion can vary 
between individuals such as gastric emptying (Leiper et al. 
2001; Rehrer et al. 1992). However, individualised strate-
gies for each participant would have required prior test-
ing, some of which may have been invasive, and so was 
not possible in the current study. In addition, while partici-
pants were instructed to consume all of the contents of each 
gel, this was not assessed systematically, and therefore, the 
possibility remains that some participants consumed less 
and, therefore, may not have reached the prescribed CHO 
intake. Sweat rates can also vary between athletes (Baker 
et al. 2016), and therefore, runners may have experienced 
differing levels of dehydration, which is also known to affect 
GI symptoms (Lambert et al. 2008; Rehrer et al. 1989). We 
did not measure core temperature during the race, which 
has been associated with both GI damage and symptoms 
(Pires et al. 2016). The cohort here had a large range of fin-
ish time, with subsequent ranges in training history and vol-
ume. Future studies should also look to recruit participants 
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of more similar characteristics, as these most likely influence 
the risk of GI symptomology.
In conclusion, we provide novel data demonstrating that 
probiotic supplementation attenuates GI symptoms dur-
ing a marathon race, an effect that is associated with the 
maintenance of running speed during the latter stages of the 
race. Probiotic supplementation also reduced the frequency 
of moderate or worse GI symptoms reported, with differ-
ences observed after 14 days of supplementation. While we 
observed differences in these subjective measures, probiotic 
supplementation had no effect on sCD14, IL-6, IL-8, IL-10, 
cortisol, or I-FABP concentrations nor or GI permeability 
(LR). Despite this, we have shown that probiotics offer a 
promising strategy to reduce the incidence and severity 
of GI symptoms in endurance runners. Therefore, athletes 
participating in endurance events, where GI symptoms are 
common and likely to affect performance could consider 
probiotic supplementation in the weeks prior to competition.
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